

# Steven M Dubinett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8931778/publications.pdf>

Version: 2024-02-01

55  
papers

2,344  
citations

257450

24  
h-index

243625

44  
g-index

57  
all docs

57  
docs citations

57  
times ranked

4522  
citing authors

#	ARTICLE	IF	CITATIONS
1	CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA. <i>Genome Biology</i> , 2017, 18, 53.	8.8	204
2	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
3	MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. <i>Cell Reports</i> , 2016, 14, 1590-1601.	6.4	174
4	Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. <i>Clinical Cancer Research</i> , 2017, 23, 4556-4568.	7.0	149
5	The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. <i>Cancer Cell</i> , 2018, 33, 905-921.e5.	16.8	135
6	Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. <i>Cell Reports</i> , 2017, 18, 601-610.	6.4	125
7	COVID-19 Vaccine Decision-making Factors in Racial and Ethnic Minority Communities in Los Angeles, California. <i>JAMA Network Open</i> , 2021, 4, e2127582.	5.9	108
8	Functional profiling of circulating tumor cells with an integrated vortex capture and single-cell protease activity assay. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 9986-9991.	7.1	105
9	Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	101
10	Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. <i>Cancer Research</i> , 2017, 77, 6119-6130.	0.9	92
11	Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells. <i>Cell Stem Cell</i> , 2020, 27, 663-678.e8.	11.1	86
12	Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. <i>Nature Communications</i> , 2019, 10, 1856.	12.8	70
13	Chronic IL-1 $\beta$ -induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 377.	3.3	65
14	The Biology of Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 25-38.	2.1	52
15	Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3295-3308.	0.9	51
16	Drug Development for Metastasis Prevention. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 449-473.	0.4	48
17	Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. <i>Cancer Discovery</i> , 2021, 11, 714-735.	9.4	45
18	Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers. <i>Cancer Research</i> , 2015, 75, 4910-4922.	0.9	41

#	ARTICLE	IF	CITATIONS
19	Chemokines. <i>Cancer Journal (Sudbury, Mass )</i> , 2010, 16, 325-335.	2.0	39
20	The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy. <i>Cancer Research</i> , 2019, 79, 5022-5033.	0.9	37
21	Regression of Recurrent Respiratory Papillomatosis With Celecoxib and Erlotinib Combination Therapy. <i>Chest</i> , 2009, 136, 924-926.	0.8	35
22	Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 3298-3306.	4.1	32
23	p38 MAPK mediates epithelial-mesenchymal transition by regulating p38IP and Snail in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 60, 81-89.	1.5	32
24	Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 9032.	3.3	31
25	Comorbidity and thirty-day hospital readmission odds in chronic obstructive pulmonary disease: a comparison of the Charlson and Elixhauser comorbidity indices. <i>BMC Health Services Research</i> , 2019, 19, 701.	2.2	27
26	The Role of Interleukin 1 $\beta$ in the Pathogenesis of Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100001.	1.1	27
27	Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. <i>ImmunoTargets and Therapy</i> , 2012, 2012, 7.	5.8	25
28	Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. <i>Nature Communications</i> , 2021, 12, 4172.	12.8	16
29	G1TR agonist enhances vaccination responses in lung cancer. <i>OncolImmunology</i> , 2015, 4, e992237.	4.6	15
30	Gene Expression Alterations in the Bronchial Epithelium of e-Cigarette Users. <i>Chest</i> , 2019, 156, 764-773.	0.8	15
31	CCL21 Programs Immune Activity in Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1231, 67-78.	1.6	15
32	p53 modulates NF- $\kappa$ B mediated epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 921-928.	1.5	14
33	Corticotropin-Releasing Factor Reduces Lipopolysaccharide-Induced Pulmonary Vascular Leak. <i>Immunopharmacology and Immunotoxicology</i> , 1994, 16, 139-148.	2.4	13
34	Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. <i>Cancer Research</i> , 2018, 78, 1986-1999.	0.9	13
35	Early Diagnosis and Screening for Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a037994.	6.2	13
36	Factors Associated with Differential Readmission Diagnoses Following Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <i>Journal of Hospital Medicine</i> , 2020, 15, 219-227.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Readmission Rates for Chronic Obstructive Pulmonary Disease Under the Hospital Readmissions Reduction Program: an Interrupted Time Series Analysis. <i>Journal of General Internal Medicine</i> , 2020, 35, 3581-3590.	2.6	12
38	Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2389-2400.	4.2	11
39	Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties. <i>Cancer Prevention Research</i> , 2017, 10, 514-524.	1.5	9
40	CCL21 Chemokine Therapy for Lung Cancer. <i>International Trends in Immunity</i> , 2013, 1, 10-15.	0.4	8
41	Statistical parametrization of cell cytoskeleton reveals lung cancer cytoskeletal phenotype with partial EMT signature. <i>Communications Biology</i> , 2022, 5, 407.	4.4	8
42	Lung Cancer and Immunity Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2423-2430.	2.5	7
43	Use of a Novel Polymer in an Animal Model of Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 110-117.	1.9	6
44	Loss of miR125a Expression in a Model of K-ras <sup>G12S</sup> -Dependent Pulmonary Premalignancy. <i>Cancer Prevention Research</i> , 2014, 7, 845-855.	1.5	5
45	Summarizing performance for genome scale measurement of miRNA: reference samples and metrics. <i>BMC Genomics</i> , 2018, 19, 180.	2.8	5
46	Abstract 24: Multi-feature ensemble learning on cell-free dna for accurately detecting and locating cancer. <i>Cancer Research</i> , 2021, 81, 24-24.	0.9	3
47	Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S331-S333.	2.8	2
48	Understanding the mechanisms of immune-evasion by lung cancer in the context of chronic inflammation in emphysema. <i>Journal of Thoracic Disease</i> , 2019, 11, 382-385.	1.4	2
49	Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer. <i>Cancers</i> , 2021, 13, 3595.	3.7	1
50	Lung Cancer: Evolving Concepts in Management. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 647-648.	2.1	0
51	CXCR3/CXCR3 Ligand Biological Axis Impairs RENCA Tumor Growth by a Mechanism of Immunoangiostasis. <i>FASEB Journal</i> , 2006, 20, .	0.5	0
52	Randomized phase II trial of erlotinib (E) plus high-dose celecoxib (HD-C) or placebo (P) in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7518-7518.	1.6	0
53	Characteristics of NSCLCs harboring <i>NRAS</i> mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7532-7532.	1.6	0
54	Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3026-3026.	1.6	0

#	ARTICLE	IF	CITATIONS
55	SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer. Journal of the Endocrine Society, 2020, 4, .	0.2	0